<DOC>
	<DOCNO>NCT02426125</DOCNO>
	<brief_summary>The main purpose study evaluate safety efficacy study drug ramucirumab combination docetaxel participant urothelial cancer fail prior platinum-based therapy .</brief_summary>
	<brief_title>A Study Ramucirumab ( LY3009806 ) Plus Docetaxel Participants With Urothelial Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<criteria>Have histologically cytologically confirm , locally advance unresectable metastatic urothelial ( transitional cell ) carcinoma bladder , urethra , ureter , renal pelvis . Had disease progression platinum contain regimen firstline set within 14 month complete firstline platinum regimen . Participants receive treatment one immune checkpoint inhibitor regimen eligible ( example PD1 , PDL1 , CTLA4 ) may longer interval since prior platinumcontaining therapy ( ≤24 month ) . Have life expectancy ≥3 month . Have receive one prior systemic chemotherapy regimen relapse metastatic setting . Prior treatment one prior immune checkpoint inhibitor permit consider line systemic chemotherapy . Have measurable disease nonmeasurable evaluable disease define Response Evaluation Criteria Solid Tumors , Version 1.1 ( RECIST 1.1 ) . Have Eastern Cooperative Oncology Group ( ECOG ) 0 1 . Have adequate hematologic function . Have adequate coagulation function . Have adequate hepatic function . The participant : cirrhosis level ChildPugh B ( bad ) cirrhosis ( degree ) history hepatic encephalopathy clinically meaningful ascites result cirrhosis Have adequate renal function define creatinine clearance &gt; 30 milliliters/minute . Have urinary protein ≤1+ dipstick routine urinalysis . The participant willing provide blood , urine , tissue sample research purpose . Have receive one prior systemic chemotherapy regimen metastatic disease . Have receive prior systemic taxane therapy transitional cell carcinoma ( TCC ) bladder , urethra , ureter , renal pelvis setting ( neoadjuvant , adjuvant , metastatic ) . Have receive one prior antiangiogenic agent ( , bevacizumab , sorafenib , sunitinib ) TCC urothelium . Have receive radiation therapy within 4 week ( ≤4 week ) prior randomization recover toxic effect treatment give &gt; 4 week prior randomization . Have history uncontrolled hereditary acquire bleed thrombotic disorder . Have experience Grade ≥3 bleed event within 3 month ( ≤3 month ) prior randomization . Have uncontrolled intercurrent illness , include , limited symptomatic anemia , uncontrolled hypertension , symptomatic congestive heart failure , unstable angina pectoris , symptomatic poorly control cardiac arrhythmia , psychiatric illness , serious uncontrolled medical disorder . Have experience arterial venothrombotic thromboembolic event , include , limited myocardial infarction , transient ischemic attack , cerebrovascular accident , within 6 month ( ≤6 month ) prior randomization . Have know untreated brain metastasis , uncontrolled spinal cord compression , leptomeningeal disease . Have human immunodeficiency virus ( HIV ) infection acquire immunodeficiency syndromerelated illness . Have undergone major surgery within 28 day ( ≤28 day ) prior randomization subcutaneous venous access device placement within 7 day ( ≤7 day ) prior randomization . The participant pregnant prior randomization lactating . Have concurrent malignancy another malignancy within 5 year ( ≤5 year ) study enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>carcinoma bladder</keyword>
	<keyword>carcinoma urethra</keyword>
	<keyword>carcinoma ureter</keyword>
	<keyword>carcinoma renal pelvis</keyword>
	<keyword>transitional cell carcinoma</keyword>
	<keyword>transitional cell tumor</keyword>
	<keyword>RANGE</keyword>
	<keyword>bladder cancer</keyword>
</DOC>